Unlike TCRs, which recognize antigenic peptides presented by MHC molecules, CARs allow T cells to recognize surface antigens on tumor cells in an MHC-independent manner, bypassing challenges associated with rare-tumor antigen presentation and the scarcity of antigen-specific T cells. Here, HLA-C is linked to neoplasm.